Steady ahead for Novartis following year of strategic investments

laboratory-large-1

An analysis of the investment activity of Novartis (NOVN: VX) in recent years.

Novartis full-year results in line with investor expectations

On January 31 this year, Novartis released full-year results for 2023 that were in line with investor expectations, with net sales of $45.4 billion (+8% constant currency (cc) year on year (YoY) driven by leading brands Cosentyx (secukinumab), Entresto (sacubitril/valsartan), Kesimpta (ofatumumab), and Kisqali (ribociclib), though sales of Pluvicto (lutetium (177Lu) were weaker than expected due to supply challenges which the company has already dealt with through the expansion of new manufacturing plant in the USA and China. Operating income increased by 39% (cc, YoY) to $9.8 billion and EPS up by 70% (cc, YoY) to $4.13. The company updated mid-term guidance and forecasted net sales compound average growth rate (CAGR) 2023-2028 of 5% cc. The share price closed at 89.73 up 0.33% on the day (Figure 1).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical